Investors should monitor upcoming Phase 3 top-line data in Q4 2026 as a major catalyst; the durability of response and off-treatment benefit may support premium pricing and rapid adoption if approved.
Price Chart
Executive Summary
Celldex Therapeutics presented positive Phase 2 data for barzolvolimab in chronic spontaneous urticaria (CSU), cold urticaria (ColdU), and symptomatic dermographism (SD), showing profound and sustained improvements in patient quality of life across all DLQI domains. The data support barzolvolimab’s potential as a first-in-class, disease-modifying therapy, with Phase 3 trials in CSU fully enrolled and top-line results expected in Q4 2026.
Key Facts
- Barzolvolimab demonstrated up to 71% complete response (UAS7=0) in CSU patients after 52 weeks of treatment, with 41% maintaining complete response seven months after last dose.
- 94% of CSU patients with well-controlled disease at Week 52 achieved DLQI 0/1, indicating no impact of disease on quality of life.
- 76% of these patients maintained DLQI ≤5 (small to no impact) at Week 76, off-treatment, suggesting disease modification.
- In ColdU and SD, barzolvolimab increased the rate of DLQI 0/1 by up to 3.1-fold (ColdU) and 4.0-fold (SD) vs placebo by Week 20.
- Phase 3 CSU program (EMBARQ-CSU1/CSU2) enrolled 1,939 patients across 43 countries; top-line data expected Q4 2026.
- Phase 3 trial in ColdU and SD (EMBARQ-ColdU/-SD) is ongoing with enrollment in progress.
Financial Impact
No direct financial figures disclosed, but strong clinical data increases probability of regulatory success and commercial value in large, underserved urticaria markets.
Risk Factors
- Phase 3 trials may not replicate Phase 2 results.
- Regulatory approval is not guaranteed despite promising data.
- Competition from existing and emerging biologics in allergic and inflammatory diseases.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3263841 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Jun 14, 2026 15w ago | Press Release | $32.12 $38.53 | ▼ −19.96% | ▼ −20.71% | $32.07 (+0.16%) |
Jun 14, 2026 15w ago | Press Release | $32.12 $38.53 | ▲ +19.96% | ▲ +20.71% | $32.07 (−0.16%) |
Jun 11, 2026 16w ago | Institutional Cluster | $29.96 $38.98 | ▲ +30.11% | ▲ +28.22% | $32.07 (+7.04%) |
Jun 10, 2026 16w ago | Press Release | $29.96 $38.98 | ▲ +30.11% | ▲ +28.22% | $32.07 (+7.04%) |
May 7, 2026 21w ago | 8-K | $33.97 $28.62 | ▼ −15.75% | ▼ −15.77% | $32.07 (−5.59%) |
May 7, 2026 21w ago | Press Release | $33.97 $28.62 | ▼ −15.75% | ▼ −15.77% | $32.07 (−5.59%) |
Apr 6, 2026 25w ago | Press Release | $31.37 $32.77 | ▲ +4.46% | ▼ −4.52% | $32.07 (+2.23%) |
Apr 2, 2026 26w ago | Press Release | $31.06 $32.88 | ▲ +5.86% | ▼ −4.02% | $32.07 (+3.25%) |
Apr 1, 2026 26w ago | 424B5 | $31.06 $32.88 | ▲ +5.86% | ▼ −4.02% | $32.07 (+3.25%) |
Apr 1, 2026 26w ago | Press Release | $31.06 $32.88 | ▲ +5.86% | ▼ −4.02% | $32.07 (+3.25%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access